Pembrolizumab

Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Product Specifications

CAS Number

[1374853-91-4]

Product Name Alternative

MK-3475; Lambrolizumab

UNSPSC

12352203

Hazard Statement

H360, H372

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Lambrolizumab.html

Purity

99.74

Solubility

H2O

Smiles

[Pembrolizumab]

Molecular Weight

(145.24 kDa)

Precautions

H360, H372

References & Citations

[1]Zhenglin Ou, et al. Pressure increases PD‑L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti‑ROR1 CAR T cell‑mediated cytotoxicity, Sci Rep|[2]Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21 (19) :4286-93.|[3]Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) . Lancet. 2017 Aug 16. pii: S0140-6736 (17) 31601-X.|[4]Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21 (19) :4286-93.